Wockhardt to Hold 27th AGM on August 10, 2026; Seeks Approval for ₹3,000 Crore Capital Raise
Wockhardt Limited has scheduled its 27th AGM on August 10, 2026 via VC/OAVM, seeking shareholder approval for a ₹3,000 Crore capital raise through QIP or other modes, revision of Executive Chairman Dr. Habil Khorakiwala's remuneration up to ₹15 Crore per annum, material related party transactions with subsidiaries Wockhardt Bio AG, CP Pharmaceuticals Limited and Wockhardt UK Limited, appointment of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of Wockhardt Bio AG at USD 250,000 per annum, and redeployment of approximately ₹162.33 Crore in unutilised QIP proceeds from the November 2024 placement towards R&D and capital expenditure.

*this image is generated using AI for illustrative purposes only.
Wockhardt Limited has announced the convening of its 27th Annual General Meeting (AGM) on Monday, August 10, 2026, at 3:30 p.m. (IST), to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The notice, issued pursuant to Regulations 29, 30 and 34(1) of the SEBI Listing Regulations, was filed by Company Secretary Rashmi Mamtura on July 17, 2026. The AGM shall be deemed to be held at the Registered Office of the Company at D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar – 431 006.
Key AGM Agenda Items
The meeting will transact both ordinary and special business. The ordinary business includes adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and the re-appointment of Ms. Zahabiya Khorakiwala (DIN: 00102689), who retires by rotation and offers herself for re-appointment.
The following table summarises the key resolutions proposed at the 27th AGM:
| Resolution: | Nature | Key Details |
|---|---|---|
| Cost Auditor Remuneration Ratification: | Ordinary | ₹3,85,000 plus taxes payable to Kirit Mehta & Co. LLP for FY 2026-27 |
| Executive Chairman Remuneration Revision: | Special | Up to ₹10 Crore p.a. (March 1, 2027 – February 29, 2028); ceiling of ₹15 Crore p.a. thereafter |
| RPT – Wockhardt Bio AG: | Ordinary | Aggregate value up to ₹1,000 Crore for sale of goods, services and IP transfer |
| RPT – CP Pharmaceuticals Limited: | Ordinary | Aggregate value up to ₹550 Crore for purchase/sale of goods and services |
| RPT – Wockhardt UK Limited: | Ordinary | Aggregate value up to ₹550 Crore for sale of goods and services |
| Capital Raising (QIP/Other Modes): | Special | Amount not exceeding ₹3,000 Crore via equity shares or eligible securities |
| Ms. Zahabiya Khorakiwala Appointment: | Ordinary | Executive Co-chairperson of Wockhardt Bio AG at USD 250,000 per annum w.e.f. May 4, 2026 |
| QIP Proceeds Redeployment: | Special | Redeployment of unutilised proceeds of approximately ₹162.33 Crore from November 11, 2024 QIP |
Executive Remuneration Revision
The Board of Directors and the Nomination and Remuneration Committee, at their respective meetings held on May 4, 2026, proposed a revision in remuneration payable to Dr. Habil Khorakiwala, Executive Chairman, for the remaining three years of his tenure from March 1, 2027 to February 28, 2030. The revised remuneration will be ₹10 Crore per annum for the period commencing from March 1, 2027 till February 29, 2028, which may be further revised from time to time till February 28, 2030, subject to an overall ceiling of ₹15 Crore per annum. Dr. Habil Khorakiwala was originally appointed as Executive Chairman for a term of five years at the Twenty-Fifth AGM held on June 28, 2024.
Capital Raising and QIP Proceeds Redeployment
The company seeks enabling approval to issue securities for a value not exceeding ₹3,000 Crore (Rupees Three Thousand Crore Only) or its equivalent in any foreign currency, through one or more public and/or private offerings including a Qualified Institutions Placement (QIP). The proceeds may be utilised for business purposes including capital expenditure, research and development, repayment/prepayment of long-term and short-term debt, and general corporate purposes.
Separately, shareholders will vote on the redeployment of unutilised QIP proceeds from the November 11, 2024 placement. The following table details the original use of proceeds and the current utilisation status as of March 31, 2026:
| Item Head: | Amount Proposed (₹ Crore) | Amount Utilised as of March 31, 2026 (₹ Crore) | Balance (₹ Crore) |
|---|---|---|---|
| Repayment/pre-payment of borrowings: | 500.00 | 500 | 0 |
| Capital expenditure, R&D and incidental expenses: | 250.00 | 87.67 | 162.33 |
| General corporate purposes: | 227.79 | 227.79 | 0 |
| Total: | 977.79 | 815.46 | 162.33 |
The company proposes to redeploy the unutilised balance of approximately ₹162.33 Crore towards funding capital expenditure and investment in targeted R&D activities encompassing Biosimilar, New Chemical Entities (NCE) and other products. The Board of Directors has also extended the timeline for utilisation of such funds from financial year 2026 up to financial year 2028.
Material Related Party Transactions
The company seeks member approval for material related party transactions with three subsidiaries. Transactions with Wockhardt Bio AG — a subsidiary in which Wockhardt holds 85.85% — include sale of goods, recovery of management and technical fees, and transfer of Intellectual Property Rights, with an aggregate value up to ₹1,000 Crore. During FY 2025-26, transactions with Wockhardt Bio AG aggregated to ₹584.33 Crore. Proposed transactions between Wockhardt Bio AG and CP Pharmaceuticals Limited (a step-down subsidiary) and between Wockhardt Bio AG and Wockhardt UK Limited are each capped at ₹550 Crore.
Ms. Zahabiya Khorakiwala's Appointment at Wockhardt Bio AG
The Board approved the appointment of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of Wockhardt Bio AG with effect from May 4, 2026, at a remuneration of USD 250,000 per annum, together with such benefits and reimbursements as may be approved in accordance with applicable policies. Her responsibilities will include market access strategy, stakeholder engagement, and partnership development for the company's Global NCE portfolio with a focus on the United States and allied markets.
E-Voting and AGM Schedule
Key dates for the AGM process are as follows:
| Parameter: | Details |
|---|---|
| AGM Date: | Monday, August 10, 2026 at 3:30 p.m. (IST) |
| Record/Cut-off Date: | Monday, August 3, 2026 |
| E-Voting Start: | Friday, August 7, 2026 at 9:00 a.m. (IST) |
| E-Voting End: | Sunday, August 9, 2026 at 5:00 p.m. (IST) |
| Speaker Registration Window: | July 31, 2026 (9:00 a.m.) to August 6, 2026 (5:00 p.m.) |
E-voting services are being provided by NSDL. Mr. Virendra Bhatt, Practicing Company Secretary (ACS No. 1157, CP No. 124/Peer Review Certificate No. 6489/2025), has been appointed as Scrutinizer for the remote e-voting process.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE049B01025/1aaad7bf-1ec6-4ac2-97dc-2c8a6234d2b3.pdf
Historical Stock Returns for Wockhardt
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.30% | +3.79% | -0.96% | +33.14% | +4.38% | +260.03% |
What specific strategic initiatives or acquisitions is Wockhardt targeting with the proposed ₹3,000 Crore capital raising?
How will the significant increase in the Executive Chairman's remuneration impact shareholder sentiment and governance perceptions?
What are the expected revenue contributions from the Global NCE portfolio that Ms. Zahabiya Khorakiwala will focus on?































